(1-氨基环己基)二甲胺 | 41806-09-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1-氨基环己基)二甲胺
• 中文别名: 1-(二甲基氨基)环己烷甲胺
• 英文名称: 1-aminomethyl‐1‐cyclohexanedimethylamine
• 英文别名: 1-aminomethyl-1-dimethylaminocyclohexane；(1-aminomethyl-cyclohexyl)dimethylamine；1-aminomethyl-1-cyclohexyldimethylamine；1-(aminomethyl)-N,N-dimethylcyclohexylamine；1-{1-(dimethylamino)cyclohexyl}methylamine；1-aminomethylcyclohexyldimethylamine；1-(aminomethyl)-N,N-dimethylcyclohexan-1-amine
• CAS: 41806-09-1
• 化学式: C₉H₂₀N₂
• mdl: MFCD05201342
• 分子量: 156.271
• InChiKey: TYMAJBZHTKCAJJ-UHFFFAOYSA-N

物化性质

• 沸点：
  189℃
• 密度：
  0.92
• 闪点：
  69℃

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2921300090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (1-Aminomethylcyclohexyl)dimethylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (1-Aminomethylcyclohexyl)dimethylamine
CAS number: 41806-09-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H20N2
Molecular weight: 156.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1-氨基环己基)二甲胺 在 sodium hydroxide 、 乙酸酐 、 sodium carbonate 作用下， 生成 acetamidomethylcyclohexyl-dimethylamine
  参考文献：
  名称：

  1-(3,4-DICHLOROBENZAMIDOMETHYL)-CYCLOHEXYLDIMETHYLAMINE

  摘要：

  通式I的化合物：##EQU1##其中R.sup.1 - R.sup.4可能相同也可能不同，代表氢原子，或C.sub.1-6直链或支链烷基，烯基或炔基或被环烷基取代的烷基，或代表环烷基，烷氧羰基，芳基，芳基烷基，酰基（包括任何磺酰基）基团，其中烷基或芳基烷基的烷基部分可以被一个或多个羟基或酯化羟基基团取代，芳基或酰基或芳基烷基的芳基部分可以被一个或多个卤素原子，烷基基团，羟基基团，烷氧基团，三氟甲基，硝基，氨基或二烷基氨基基团取代，且R.sup.5 - R.sup.8可能相同也可能不同，代表氢原子或烷基基团，除非所有基团都是氢原子，或R.sup.5和R.sup.6或R.sup.7和R.sup.8一起代表一个羰基（=O）氧原子，在R.sup.1 /R.sup.2，R.sup.3 /R.sup.4，R.sup.5 /R.sup.6和R.sup.7 /R.sup.8中的任何一对基团中，可能代表一个由较低烷基或芳基基团取代的脂环或杂环系统，所述环饱和或不饱和。这些化合物在口服止痛剂中具有应用价值。

  公开号：

  US03975443A1
• 作为产物：
  描述：

  环己酮 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 乙醚 、 水 为溶剂， 反应 32.0h， 生成 (1-氨基环己基)二甲胺
  参考文献：
  名称：

  乙二胺合成阿片类药物在人 μ-阿片受体 1 (OPRM1) 表达细胞中的合成和药理学表征。

  摘要：

  阿片类药物是强效镇痛药，通过人类 μ-阿片受体 (hMOR) 发挥作用。阿片类药物的使用与耐受、成瘾、呼吸抑制和便秘等不良反应有关。两种合成阿片类药物 AH-7921 和 U-47700 于 20 世纪 70 年代开发，但从未上市，最近出现在非法药物市场和法医毒理学报告中。这些药物最初的特点是在啮齿类动物中具有镇痛活性；然而，它们在 hMOR 上的药理学尚未描述。因此，我们基于核心 AH-7921 和 U-47700 结构合成了 50 多种化学类似物，以评估它们与 Gαi 信号传导偶联并诱导 hMOR 内化的能力。对于 AH-7921 和 U-47700 类似物，3,4-二氯苯甲酰取代基是最有效的，具有可比的 EC50 值来抑制 cAMP 积累；分别为 26.49 ± 11.2 nmol L-1 和 8.8 ± 4.9 nmol L-1。尽管 Gαi 偶联的效力相似，但这两种化合物具有显着不同的

  DOI：

  10.1002/prp2.511

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF
  申请人：VIVOZON, INC.

  公开号：US20140336378A1

  公开（公告）日：2014-11-13

  Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

  揭示了一种新的苯甲酰胺衍生物及其药用，更具体地说，一种具有化学式1结构或其药用盐的新苯甲酰胺衍生物，以及包括上述材料的用于预防或治疗疼痛或瘙痒的组合物。根据本发明，所述新的苯甲酰胺衍生物及其药用盐表现出优异的镇痛效果，特别是在不仅神经病理动物模型中而且其他模型如福尔马林模型中表现出的镇痛效果，因此，可用于抑制不同类型的疼痛，如伤害性疼痛、慢性疼痛等。此外，由于证明了本发明在瘙痒模型中显示出抗瘙痒功效，应用于疼痛方面建立的机制和治疗概念，因此，本发明还可通过将创新产品应用于抗瘙痒组合物中，以抑制初始瘙痒阶段并治疗其症状，从而预防刮痒阶段后的皮肤损伤或炎症。
• DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND
  申请人：Shimada Itsuro

  公开号：US20120040968A1

  公开（公告）日：2012-02-16

  Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.

  提供的是一种化合物，可作为抑制EML4-ALK融合蛋白激酶活性的抑制剂。通过对具有抑制EML4-ALK融合蛋白激酶活性的化合物进行深入广泛的研究，本发明人发现本发明的二氨基杂环羧酰胺化合物对EML4-ALK融合蛋白激酶活性具有抑制作用。通过这一发现，完成了本发明。本发明的化合物可用作预防和/或治疗癌症，如肺癌、非小细胞肺癌和小细胞肺癌的药物组合物。
• [EN] INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'INDOLE CARBOXAMIDE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014097140A1

  公开（公告）日：2014-06-26

  The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  这项发明涉及式(I)的吲哚羧酰胺衍生物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和n如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。
• Reaching out for Sensitive Evaluation of the Mu Opioid Receptor in Vivo: Positron Emission Tomography Imaging of the Agonist [¹¹C]AH7921
  作者：Waqas Rafique、Shivashankar Khanapur、Mona M. Spilhaug、Patrick J. Riss

  DOI：10.1021/acschemneuro.7b00075

  日期：2017.9.20

  Imaging of the mu opioid receptor (MOR) availability with positron emission tomography (PET) is a pertinent challenge in Neuroscience. Both, regulation of receptor expression and occupancy by endogeneous opioids play into cognitive and behavioral phenotypes of healthy function and disease. Receptor expression in the active and inactive states can be measured using high affinity radioagonist and radioantagonist

  使用正电子发射断层扫描（PET）对mu阿片受体（MOR）的可用性进行成像是Neuroscience中的一个相关挑战。内源性阿片样物质对受体表达和占有率的调节都参与了健康功能和疾病的认知和行为表型。可以分别使用高亲和力放射性激动剂和放射性拮抗剂PET示踪剂测量处于活跃状态和非活跃状态的受体表达。占用评估要求放射性配体显示出竞争性和可逆的结合力，与MOR的亲和力适中，这可能导致体内受体特异性信号的物理灭绝。我们研究了大鼠中度有效的选择性MOR激动剂，以测试专门为与内源性阿片类药物竞争而设计的放射性示踪剂设计范式是否会产生可行的成像结果。苯甲酰胺3，1）是使用放射自显影和正电子发射断层扫描在大鼠大脑中合成和表征的。发现化合物1以低纳摩尔效能活化MOR，并以较小程度的KOR作为完全激动剂活化。进行了激动剂和拮抗剂放射性配体的浓度依赖性结合研究，以评估竞争行为并获得抑制常数。动力学分析大鼠脑中3,4-二氯苯[